Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ryan Trout

Physician Assistant, Medical Mount Pleasant, SC Physician Assistant

NPI 1114594124 CMS profile 11301213

612 Seacoast Pkwy, Mount Pleasant, SC 29464

Open in the dashboard

General payments

$10,932

380 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Trout of Mount Pleasant, SC is reported in the CMS Open Payments database as having received $10,932 across 380 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,999 106
2024 General $3,636 102
2023 General $1,834 79
2022 General $1,760 69
2021 General $703 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Trout
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Ryan Trout were reported at $2,999. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Ryan Trout Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $703 $156 $41–$563 $132
2022 $1,760 $185 $55–$649 $149
2023 $1,834 $199 $58–$717 $160
2024 $3,636 $206 $62–$740 $164
2025 $2,999 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,232 41 payments
  2. Sun Pharmaceutical Industries Inc. $1,033 41 payments
  3. Galderma Laboratories, L.P. $963 26 payments
  4. Janssen Biotech, Inc. $900 25 payments
  5. Genzyme Corporation $879 32 payments
  6. Novartis Pharmaceuticals Corporation $772 31 payments
  7. E.R. Squibb & Sons, L.L.C. $658 14 payments
  8. Dermavant Sciences, Inc. $627 22 payments
  9. Lilly USA, LLC $575 25 payments
  10. Incyte Corporation $495 16 payments
  11. Other $2,797 107 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,191 371 payments
  2. Education $741 9 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $1,118 44 payments
  2. TREMFYA $1,011 27 payments
  3. VTAMA $736 24 payments
  4. SOTYKTU $658 14 payments
  5. RINVOQ $644 17 payments
  6. TALTZ $544 24 payments
  7. COSENTYX $517 21 payments
  8. SKYRIZI $467 17 payments
  9. NEMLUVIO $449 17 payments
  10. ILUMYA $445 29 payments
  11. Other $3,954 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

452

Median for Physician Assistant: 241

Drug cost

$275,807

Median for Physician Assistant: $4,110

Branded share of claims

2.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 13 $268,003
Betamethasone Dipropionate Generic 56 $2,252
Clobetasol Propionate Generic 48 $1,568
Fluorouracil Generic 17 $1,380
Ketoconazole Generic 100 $948
Doxycycline Hyclate Generic 45 $710
Triamcinolone Acetonide Generic 64 $390
Hydrocortisone Generic 78 $387
Mupirocin Generic 20 $121
Prednisone Generic 11 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$61,631

Medicare's payments for the services billed

Medicare patients

377

Average age 73

Services billed

2,069

173 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 42%
Diabetes 27%
Ischemic heart disease 23%
Depression 21%
Atrial fibrillation 17%
Chronic kidney disease 16%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $467
$467 — —
RINVOQ
  • AbbVie, Inc. $379
$379 — —
TREMFYA
  • Janssen Biotech, Inc. $293
  • Janssen Scientific Affairs, LLC $77
$370 — —
DUPIXENT
  • GENZYME CORPORATION $221
  • Regeneron Healthcare Solutions, Inc. $141
$362 — —
SKYRIZI
  • AbbVie, Inc. $309
$309 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

380 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record